{
    "doi": "https://doi.org/10.1182/blood.V106.11.5404.5404",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=353",
    "start_url_page_num": 353,
    "is_scraped": "1",
    "article_title": "Second Neoplasm after Bone Marrow Transplant (BMT). ",
    "article_date": "November 16, 2005",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "Introduction: the second neoplasm, are pathologies described during the post transplant evolution, often associated to immunosuppression. The post transplant lymphoproliferative syndromes, habitually associated to viruses are the most frequent. The BMT is a procedure clearly different from the rest of the transplants, and this difference would also be observed on the incidence and type of tumor in its evolution. The incidence of second malignancies after BMT is low, and is related to the use of chemotherapy, particulary alkylating. agents radiotheraphy and immunosuppression. Objective: To analyze the incidence and characteristics of second neoplasm of the patients undergoing BMT in our Institute. Results: Between 06/93 and 04/05 over a total of 416 transplants, 132 Allogenic and 284 Autologous, 6 cases of second tumor in variable intervals post procedure were stated. Table 1. The data reflects an incidence of second neoplasias of 1,4% (6/416). None of then received radiotherapy in conditioning. No lymphoproliferative syndrome was observed; 2 cases of acute leukemias; being the rest solid tumors with expected evolutions for each pathology. Table 1  Case . Disease . Conditioning . BMT . 2nd Tumor . Time betwen BMT-Tumor . Evolution . 1 MM L-PAM AUTO Lung Cancer 120 months Dead 2 CML BuCy ALLO Colon Cancer 72 months Dead 3 MDS BuCy ALLO Merckel cells tumor 60 months Dead 4 NHL CBV AUTO AML 65 months Dead 5 NHL CBV AUTO Bladder Cancer 58 months Alive 26 months 6 NHL CBV AUTO AML 4 months Dead Case . Disease . Conditioning . BMT . 2nd Tumor . Time betwen BMT-Tumor . Evolution . 1 MM L-PAM AUTO Lung Cancer 120 months Dead 2 CML BuCy ALLO Colon Cancer 72 months Dead 3 MDS BuCy ALLO Merckel cells tumor 60 months Dead 4 NHL CBV AUTO AML 65 months Dead 5 NHL CBV AUTO Bladder Cancer 58 months Alive 26 months 6 NHL CBV AUTO AML 4 months Dead View Large",
    "topics": [
        "bone marrow transplantation",
        "neoplasms, second primary",
        "neoplasms",
        "allopurinol",
        "therapeutic immunosuppression",
        "transplantation",
        "bladder cancer",
        "chemotherapy regimen",
        "colon cancer",
        "colorectal cancer"
    ],
    "author_names": [
        "Jorge H. Milone, MD",
        "Juan J. Napal, MD",
        "Javier A. Bordone, MD",
        "Virginia Prates, MD",
        "Cecilia Garcia, MD",
        "Victor H. Morales, MD",
        "Orlando J. Etchegoyen, MD"
    ],
    "author_affiliations": [
        [
            "ITMO, Instituto de Trasplante de Medula Osea, La Plata, Argentina"
        ],
        [
            "ITMO, Instituto de Trasplante de Medula Osea, La Plata, Argentina"
        ],
        [
            "ITMO, Instituto de Trasplante de Medula Osea, La Plata, Argentina"
        ],
        [
            "ITMO, Instituto de Trasplante de Medula Osea, La Plata, Argentina"
        ],
        [
            "ITMO, Instituto de Trasplante de Medula Osea, La Plata, Argentina"
        ],
        [
            "ITMO, Instituto de Trasplante de Medula Osea, La Plata, Argentina"
        ],
        [
            "ITMO, Instituto de Trasplante de Medula Osea, La Plata, Argentina"
        ]
    ],
    "first_author_latitude": "-34.9205283",
    "first_author_longitude": "-57.95317029999999"
}